Literature DB >> 28784969

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections.

Jessica X Yuan1, Jennifer M Munson2.   

Abstract

With the growing interest in the tumor microenvironment, we set out to develop a method to specifically determine the microenvironment components within patient samples of glioblastoma, the deadliest and most invasive brain cancer. Not only are quantitative methods beneficial for accurately describing diseased tissues, they can also potentially contribute to more accurate prognosis, diagnosis, and the development of tissue-engineered systems and replacements. In glioblastoma, glial cells, such as microglia and astrocytes, have been independently correlated with poor prognosis based on pathologist grading. However, the state of these cells and other glial cell components has not been well-described quantitatively. This can be difficult due to the large processes that mark these glial cells. Furthermore, most histological analyses focus on the overall tissue sample or only within the bulk of the tumor, as opposed to delineating quantifications based on regions within the highly heterogeneous tissue. Here, we describe a method for identifying and quantitatively analyzing the populations of glial cells within the tumor bulk and adjacent regions of tumor resections from glioblastoma patients. We used chromogenic immunohistochemistry to identify the glial cell populations in patient tumor resections and ImageJ to analyze percent coverage of staining for each glial population. With these techniques we are able to better describe the glial cells throughout regions of the glioma tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28784969      PMCID: PMC5613923          DOI: 10.3791/56025

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  24 in total

Review 1.  Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma.

Authors:  Tercia Rodrigues Alves; Flavia Regina Souza Lima; Suzana Assad Kahn; Denise Lobo; Luiz Gustavo Feijó Dubois; Rossana Soletti; Helena Borges; Vivaldo Moura Neto
Journal:  Life Sci       Date:  2011-05-18       Impact factor: 5.037

2.  Microglia/macrophages promote glioma progression.

Authors:  Haiyan Zhai; Frank L Heppner; Stella E Tsirka
Journal:  Glia       Date:  2010-12-29       Impact factor: 7.452

Review 3.  Role of microglia in glioma biology.

Authors:  B Badie; J Schartner
Journal:  Microsc Res Tech       Date:  2001-07-15       Impact factor: 2.769

4.  Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.

Authors:  Duc M Le; Arnaud Besson; Darrin K Fogg; Kyu-Sil Choi; David M Waisman; Cynthia G Goodyer; Barry Rewcastle; V Wee Yong
Journal:  J Neurosci       Date:  2003-05-15       Impact factor: 6.167

5.  Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling.

Authors:  Yinyin Yuan; Henrik Failmezger; Oscar M Rueda; H Raza Ali; Stefan Gräf; Suet-Feung Chin; Roland F Schwarz; Christina Curtis; Mark J Dunning; Helen Bardwell; Nicola Johnson; Sarah Doyle; Gulisa Turashvili; Elena Provenzano; Sam Aparicio; Carlos Caldas; Florian Markowetz
Journal:  Sci Transl Med       Date:  2012-10-24       Impact factor: 17.956

Review 6.  The tumor microenvironment is a dominant force in multidrug resistance.

Authors:  Ana Luísa Correia; Mina J Bissell
Journal:  Drug Resist Updat       Date:  2012-02-13       Impact factor: 18.500

7.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

Authors:  Naoki Shinojima; Kenji Tada; Shoji Shiraishi; Takanori Kamiryo; Masato Kochi; Hideo Nakamura; Keishi Makino; Hideyuki Saya; Hirofumi Hirano; Jun-Ichi Kuratsu; Koji Oka; Yasuji Ishimaru; Yukitaka Ushio
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

Review 8.  The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment.

Authors:  Amanda L Placone; Alfredo Quiñones-Hinojosa; Peter C Searson
Journal:  Tumour Biol       Date:  2015-10-22

9.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

10.  IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.

Authors:  Qi SongTao; Yu Lei; Gui Si; Ding YanQing; Han HuiXia; Zhang XueLin; Wu LanXiao; Yao Fei
Journal:  Cancer Sci       Date:  2011-11-28       Impact factor: 6.518

View more
  2 in total

1.  MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.

Authors:  Xin-Long Ma; Feng Shang; Wei Ni; Jin Zhu; Bin Luo; Yu-Qi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-09-17       Impact factor: 4.553

2.  Transcription factor PU.1 is involved in the progression of glioma.

Authors:  Yuanzhi Xu; Song Gu; Yunke Bi; Xiangqian Qi; Yujin Yan; Meiqing Lou
Journal:  Oncol Lett       Date:  2018-01-10       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.